Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome

Scand J Infect Dis. 1995;27(3):241-3. doi: 10.3109/00365549509019016.


Guillain-Barre syndrome is an acquired demyelinating polyneuropathy that is presumed to be immune-mediated. On the basis of this assumption, intravenous immunoglobulin (IVIG) has been used in the treatment of Guillain-Barre syndrome in recent years and found to be effective. To test this we performed a randomized study in patients with Guillain-Barre syndrome by giving IVIG (1 g/kg body weight per day over 2 consecutive days) in 9 children who were compared with 9 patients who were observed but not given specific therapy. We concluded that intravenous immunoglobulin is a safe and effective treatment for childhood Guillain-Barre syndrome which shortens the time to recovery.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Child
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Male
  • Polyradiculoneuropathy / physiopathology
  • Polyradiculoneuropathy / therapy*
  • Prognosis
  • Respiration, Artificial


  • Immunoglobulins, Intravenous